Haemonetics Corp officer Maryanne Farris filed a Form 144 notice of proposed sale on November 12, 2026, covering 836 shares of Haemonetics common stock with an aggregate market value of $101,144.38.

Key Highlights

  • Proposed seller: Maryanne Farris, identified in the filing as an officer of Haemonetics Corp.
  • Shares proposed for sale: 836 shares of common stock, with an aggregate market value of $101,144.38.
  • Shares outstanding: 45,537,511 shares of common stock outstanding, according to the filing.
  • Approximate date of sale: November 11, 2026, through Fidelity Brokerage Services LLC.
  • Sources of shares: Four separate acquisition transactions - restricted stock vestings on May 15, 2024 (137 shares), May 15, 2025 (150 shares), and May 17, 2025 (127 shares), plus a stock option exercise on November 11, 2026 (422 shares).
  • Prior three-month sales: The filing reports nothing to disclose for securities sold during the past three months.

Haemonetics Officer Farris Proposes Sale of 836 Common Shares via Rule 144

According to the Form 144 filed with the U.S. Securities and Exchange Commission on November 12, 2026, Maryanne Farris, an officer of Haemonetics Corp (NYSE:HAE), is proposing to sell 836 shares of the company's common stock. The filing lists Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917, as the named broker for the transaction. The aggregate market value of the proposed sale is stated as $101,144.38.

The filing details four distinct acquisitions underlying the shares proposed for sale. Three acquisitions resulted from restricted stock vesting events: 137 shares vested on May 15, 2024; 150 shares vested on May 15, 2025; and 127 shares vested on May 17, 2025. All three vesting transactions were acquired from the issuer and classified as compensation. The fourth acquisition consisted of a stock option exercise on November 11, 2026, through which Farris acquired 422 shares from the issuer, with payment made in cash.

The filing indicates there are no securities sold during the past three months to report. The notice was signed by Gary Redman as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Maryanne Farris. Haemonetics Corp is headquartered at 125 Summer Street, Boston, Massachusetts 02110, and carries SEC File Number 001-14041.

What Was Disclosed

Haemonetics officer Maryanne Farris filed a Form 144 on November 12, 2026, notifying the SEC of a proposed sale of 836 common shares with an aggregate market value of $101,144.38, sourced from restricted stock vestings and a stock option exercise.